Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release.

Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA and MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody and assay development. Cygnus’ quality management program and processes are ISO-9001:2015 certified.

Cygnus Technologies, headquartered in Southport, North Carolina, was founded in 1997 and is online at www.cygnustechnologies.com.

Products :

• HCP Kits

• Protein A / Protein A Mix-N-Go Kits

• HCP And Protein A Related Products

• Stablizers/ Liquid Substrate/ Sample Dilution Buffers

• Immunogenicity Analysis Kits and Related Products

• DNA Kits and Related Products

• Western Blot Kits

• Antibodies

• Antigen Concentrates

• Antigens

• Other ELISA Kits